Uro PACA

13ÈME ÉDITION 2026

le Programme

Synthèse Uro-Onco

les temps forts de



03-04 DEC. 2026

Palais des Congrès · SAINT-RAPHAËL



Avec le soutien de :

AFU Association Française d'Urologie

AFUF Association Française des Urologues en Formation

SIGU Société d'Imagerie Génito-Urinaire

Académie Internationale de Pathologie – Division Française

Collège Français des Enseignants d'Urologie

CFEIU

UroPACA 2026 Program

Thursday, December 3, 2026

08:50 - 09:00

Welcome Address & Institutional Sequence

08:50 - 09:00
Welcome Address & Institutional Sequence: Introduction & opening address by the Secretary General of the AFU
Secretary General of the AFU
Prof. Julien BRANCHEREAU, Dr Olivier ALENDA

09:00 - 09:30

THE UROPACA TRIALS: Trial of systematization

Moderators: Prof. Michel SOULIÉ, Dr Aude FLÉCHON, Prof. Romain MATHIEU

09:00 - 09:15
PROSTATE Prosecution (The Blind Triplet): “Defendant, please stand: You initiated a therapeutic triplet (Castration + Docetaxel + ARPI) in a de novo mHSPC without evaluating his cardiovascular health or cognition (ARACOG data).”
Dr Carole HELISSEY

09:15 - 09:30
PROSTATE Prosecution (Rigid Surveillance): “Defendant, please stand: You continue to offer rigid active surveillance for an ISUP 2 score without genomic profiling or molecular scores.”
Dr Michaël BABOUDJIAN

09:30 - 10:00

SPECIAL SESSION: THE MDT SURVIVAL GUIDE

Moderators: Prof. Michel SOULIÉ, Dr Aude FLÉCHON, Prof. Romain MATHIEU

“What can we actually prescribe or offer on Monday morning?”

09:30 - 09:40
Active marketing authorizations & reimbursements in France: Overview of the drugs immediately available by stage.
Dr Benjamin AUBERGER

09:40 - 09:50
Early Access (AAC / CPC): Which drugs are available through early access today (e.g. HIF inhibitors, next-generation ADCs, neoadjuvant combinations) and for exactly which patient profiles?
Prof. Yann NEUZILLET

09:50 - 10:00
Referral to Clinical Trials: Which therapeutic windows remain open for enrolling our patients through the MDT (active national/regional trials) in case of an impasse, or to avoid a loss of chance?
• Summary sheet type “MDT Memo” downloadable via QR code by the audience.
Dr Maud VELEV

10:00 - 10:30

BREAK AND EXHIBITION VISIT

10:30 - 10:50

CURIUM SYMPOSIUM

Moderator: Prof. Sébastien CROUZET

10:30 - 10:50

Impact of PSMA PET in the initial staging of prostate cancer.

• Objectives: When to use PSMA compared with conventional imaging (scintigraphy/CT scan) and what direct impact for the urologist/radiotherapist.

Dr Charles MERLIN

10:50 - 11:10

MSD SYMPOSIUM

10:50 - 11:10

Hypoxia and kidney cancer: new therapeutic opportunities with HIF inhibitors

Prof. Pierre BIGOT, Dr Delphine BORCHIELLINI

11:10 - 11:50

ASTELLAS SYMPOSIUM

11:10 - 11:50

Personalizing management in uro-oncology at the heart of therapeutic decisions. mHSPC and metastatic urothelial carcinoma: which strategies in 2026?

Dr Maxime SOUQUET BRESSAND, Dr Magalie TARDY

11:50 - 12:30

BAYER SYMPOSIUM

Moderator: Prof. Romain MATHIEU

mHSPC Prostate Cancer

11:50 - 12:10

State of the art in the management of mHSPC

Prof. Yann NEUZILLET

12:10 - 12:30

How to personalize treatment at the mHSPC stage?

Dr Nicolas BENZIANE

12:30 - 14:00

PROTECTED LUNCH BREAK AND VISIT OF THE EXHIBITION

14:00 - 14:30

RED CARD

Moderators: Dr Carole HELISSEY, Prof. Christophe HENNEQUIN, Prof. Jean-Luc DESCOTES

14:00 - 14:15
Prostate: “Detectable PSA after prostatectomy: should we treat the PSA or the patient? early on, with which weapons, before turning a biological alert into therapeutic escalation? And how long should we wait?”
Dr Alban MACAGNO

14:15 - 14:30
Germ cell tumor: “Red card to endless chemotherapy: when to hand over to the surgeon?”
Prof. Xavier DURAND

14:30 - 15:10

CHANGES IN YOUR PRACTICE ACCORDING TO THE NEW GUIDELINES (CCAFU)

Moderators: Dr Carole HELISSEY, Prof. Christophe HENNEQUIN, Prof. Jean-Luc DESCOTES

14:30 - 14:40
KIDNEY PATHWAY
Prof. Pierre BIGOT

14:40 - 14:50
BLADDER PATHWAY
Prof. Yann NEUZILLET

14:50 - 15:00
PROSTATE PATHWAY
Prof. Romain MATHIEU

15:00 - 15:10
EXTERNAL GENITALIA (OGE) AND ADRENAL PATHWAY
Prof. Pierre-Henri SAVOIE

15:10 - 15:30

KIDNEY: WHEN GUIDELINES ARE NO LONGER ENOUGH?

Moderators: Dr Carole HELISSEY, Prof. Christophe HENNEQUIN, Prof. Jean-Luc DESCOTES

15:10 - 15:30
Oligometastatic recurrence of kidney cancer: aim for NED then treat, or intensify upfront?
Dr Ronan FLIPPOT

15:30 - 15:50

CLOSING THE TABOOS: “Do as I say, not as I do”

Moderators: Dr Carole HELISSEY, Prof. Christophe HENNEQUIN, Prof. Jean-Luc DESCOTES

Candid confessional session with permanent live audience voting

15:30 - 15:40
“Why I do NOT routinely perform a renal biopsy before nephrectomy”
Prof. Arnaud MÉJEAN

15:40 - 15:50
“Which 2026 novelty have I already included in my presentations, but not yet in my practice”
Prof. Karim BENSALAH

15:50 - 16:10

SUPPORT & SIMULATION SESSION (AFUF Partnership)

Moderators: Dr Carole HELISSEY, Prof. Christophe HENNEQUIN, Prof. Jean-Luc DESCOTES

15:50 - 16:10
“The decline of open surgery and laparoscopy in the face of all-robot surgery: How do we train the younger generation to manage a major complication without a console?”
• Debate: Sustainability of emergency conversion skills in surgery
Prof. Julien BRANCHEREAU, Prof. Sébastien CROUZET

16:10 - 16:30

BREAK AND EXHIBITION VISIT

16:30 - 16:50

BMS SYMPOSIUM

16:30 - 16:50
Does the subcutaneous route of immunotherapy facilitate the patient pathway and oncology facility operations?
Prof. Stéphane OUDARD, Registered nurse

16:50 - 17:10

PFIZER SYMPOSIUM

16:50 - 17:10
PARP inhibitors in prostate cancer: updates and perspectives
Dr Aude FLÉCHON

17:10 - 17:40

INNOVATIVE SESSION WITH AI, THE MICROBIOTA & THE INTRAOPERATIVE SETTING

Moderators: Prof. Arnaud MÉJEAN, Prof. Sébastien CROUZET

17:10 - 17:20
AI in your daily practice
“Does my predictive segmentation algorithm replace my expert eye for planning the resection?”
Prof. Matthieu DURAND

17:20 - 17:30
Microbiota
“Gut flora analysis: the ultimate biomarker before starting immunotherapy?”
Dr Pierre GARCIA

17:30 - 17:40
Innovation
“Intraoperative use of confocal laser endomicroscopy: gadget or revolution for surgical margins?”
Dr Wissam ABOU CHEDID

17:40 - 18:00

THE UROPACA CULTURAL INTERLUDE

17:40 - 18:00

“Illness and the allegorical representation of health in Nabis painting at the end of the 19th century.”

The spirit: 20 minutes of artistic breathing space away from the operating room to analyze how pre-modern art (Bonnard, Vuillard, Maurice Denis) captured bodily vulnerability and the concept of healing.

Prof. Marc Olivier BITKER

Friday, December 4, 2026

08:50 - 09:00

Welcome Address & Institutional Sequence

08:50 - 09:00
Introduction & opening address by the President of the AFU
Dr Antoine FAIX, Dr Olivier ALENDA

09:00 - 10:30

SHOCK SESSION: THE FUTURE OF CYSTECTOMY: Bladder tumors: from systematic resection to tailored surgery

Moderators: Prof. Thierry LEBRET, Prof. Nadine HOUEDE, Dr Jean-François BERDAH

Act 1: NMIBC — From endovesical treatment to sparing surgery

09:00 - 09:10
For the advances: Sustained-release devices (TAR-200), gene therapies and local/systemic immunotherapies.
The challenge: Management of high-risk disease (T1, CIS, high-grade Ta) and BCG failures.
Dr Géraldine PIGNOT

09:10 - 09:20
For early cystectomy (very high risk / non-responders) in the face of the risk of mutilating overtreatment vs. understaging.
Dr Alberto PANSADORO

Act 2: MIBC — The clash between surgery and organ preservation

09:20 - 09:30
The systemic disruption: Complete pathological response rates (pT0 > 50-60%) with ADC + anti-PD1 combinations (EV-Pembro).
Dr Benjamin AUBERGER

09:30 - 09:40
Biomarkers & Imaging: Is cystectomy necessary in complete responders (negative ctDNA, VI-RADS 1)?
Prof. François AUDENET

09:40 - 09:50
Modern trimodality: Role of TURBT + Radiotherapy (SBRT/IGRT) + Radiosensitization regimens to match overall survival with bladder preservation.
Dr Emmanuel GROSS

Act 3: Robotic surgery — Redefining modern cystectomy

09:50 - 10:05
Robotic cystectomy and intracorporeal reconstruction: how far should we go to preserve quality of life?
Dr Laurent LOPEZ

10:05 - 10:20
Salvage cystectomy after conservative treatment: when surgery becomes a real headache!
Prof. Filippo ANNINO

10:20 - 10:30
Summary & Monday morning MDT algorithm:
- Paradigm shift: From routine surgery to biomarker-guided active surveillance (Watch & Wait).
- Interactive audience vote: Evolution of the audience's convictions on the role of upfront cystectomy.

Dr Pierre-Olivier FAÏS

10:30 - 11:00

BREAK AND EXHIBITION VISIT

11:00 - 11:20

IPSEN SYMPOSIUM

11:00 - 11:20

“Real-world mRCC: from MDT to decision, how to personalize first-line therapy?”

- Metastatic patient: what role for cytoreductive nephrectomy? – 10 min.
- Patient underrepresented in phase III trials: beyond the standard patient - 10 min.

Prof. Marc-Olivier TIMSIT, Dr Carole HELISSEY

11:20 - 11:40

BREAKING NEWS

11:20 - 11:40

The big verdict on the benefits of robot-assisted surgery

Prof. Thierry PIECHAUD

11:40 - 12:20

JOHNSON & JOHNSON SYMPOSIUM

11:40 - 12:20

From disease control to quality of life: three key questions in prostate cancer.

Prof. Marc-Olivier TIMSIT, Dr Nita USDIN, Dr Alain TOLEDANO

12:20 - 13:30

LUNCH BREAK AND VISIT TO THE EXHIBITION

13:30 - 14:10

ASTRAZENECA SYMPOSIUM

13:30 - 14:10

“Management of bladder cancer, from non-muscle-invasive (NMIBC) to muscle-invasive (MIBC) forms: Current optimization and therapeutic perspectives.”

Dr Delphine BORCHIELLINI, Prof. Romain BOISSIER

14:10 - 15:10

SPECIAL SESSION DE-ESCALATION AND SURGICAL RESERVE

Moderators: Prof. Arnaud MÉJEAN, Prof. Stéphane OUDARD, Prof. Christophe HENNEQUIN, Prof. Cyrille BASTIDE

When Oncology and Radiotherapy put the scalpel on hold

14:10 - 14:20

Case 1 (Kidney): “Complete response on immunotherapy doublet: why on earth would I remove their kidney?”

- The oncologist: Maintaining systemic treatment alone

Prof. Stéphane OUDARD

14:20 - 14:30
Case 1 (Kidney): “Complete response on immunotherapy doublet: why on earth would I remove their kidney?”
- The urologist: Deferred cytoreductive nephrectomy
Dr Géraldine PIGNOT

14:30 - 14:40
Case 1 (Kidney): “Complete response on immunotherapy doublet: why on earth would I remove their kidney?”
- The radiotherapist: Closing SBRT to the residual disease.
Prof. Olivier CHAPET

14:40 - 14:50
Case 2 (Very high-risk prostate): why on earth do you still want to operate on them?
- The radiotherapist: “I can treat the prostate, the pelvis and intensify systemic treatment: what does your prostatectomy really add?”
Dr Mario TERLIZZI

14:50 - 15:00
Case 2 (Very high-risk prostate): why on earth do you still want to operate on them?
- The oncologist: “If I already consider this disease as potentially systemic, why start with the scalpel?”
Dr Aude FLÉCHON

15:00 - 15:10
Case 2 (Very high-risk prostate): why on earth do you still want to operate on them?
- The urologist: “In our eagerness to treat an invisible disease, aren’t we abandoning surgical control of the visible disease too quickly?”
Prof. Marco ODERDA

15:10 - 15:30

BREAK AND EXHIBITION VISIT

15:30 - 16:10

NOVARTIS SYMPOSIUM NOVARTIS | Reimagining Medicine

15:30 - 16:10
“Radioligand therapy (RIV): driving evolution in the management of mCRPC today, and mHSCP tomorrow?”
Dr Ophélie CASSUTO, Dr Elsa BOUILLOUX

16:10 - 16:30

ACT: SURGICAL NIGHTMARES IN ROBOTICS

Moderators: Prof. Thierry PIECHAUD, Prof. Julien BRANCHEREAU

“When the robot turns into a nightmare: how to get out of operative hell?”

16:10 - 16:30
The case: Ureteral avulsion, major vascular injury or unexpected complication during a complex robotic partial nephrectomy.
• Raw video: A real complication, unfiltered and without reassuring editing.
• Freeze frame: The incident occurs. What decision should be made?
• The experts’ challenge: How to regain control, repair and avoid the catastrophe?
• The verdict: Analysis of errors, rescue strategies and medico-legal lessons.
Dr Youness AHALLAL, Prof. Thierry PIECHAUD

With the support of:

You can submit your expense reimbursement request using the form available via the attached QR code (also available on the home page of uropaca.fr).

We warmly thank you for taking part in the UroPACA 2026 Meetings. Your presence and the richness of our discussions make this edition a wonderful moment of sharing and conviviality.

We also extend our sincere thanks to all of our partners, presented above, for their support and commitment alongside us.

To all of you, as well as to your families and loved ones, we wish a very happy holiday season, filled with joy, warmth and shared moments.

We look forward to seeing you again at a future edition!